- Home
- IONS vs BFAM Comparison
IONS vs BFAM Comparison
Compare IONS & BFAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- BFAM
- Stock Information
- Founded
- IONS 1989
- BFAM 1986
- Country
- IONS United States
- BFAM United States
- Employees
- IONS N/A
- BFAM N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- BFAM Other Consumer Services
- Sector
- IONS Health Care
- BFAM Consumer Discretionary
- Exchange
- IONS Nasdaq
- BFAM Nasdaq
- Market Cap
- IONS 6.0B
- BFAM 6.9B
- IPO Year
- IONS 1991
- BFAM 1997
- Fundamental
- Price
- IONS $32.32
- BFAM $126.51
- Analyst Decision
- IONS Buy
- BFAM Buy
- Analyst Count
- IONS 19
- BFAM 8
- Target Price
- IONS $61.24
- BFAM $138.38
- AVG Volume (30 Days)
- IONS 1.7M
- BFAM 481.4K
- Earning Date
- IONS 02-19-2025
- BFAM 02-13-2025
- Dividend Yield
- IONS N/A
- BFAM N/A
- EPS Growth
- IONS N/A
- BFAM 87.50
- EPS
- IONS N/A
- BFAM 2.40
- Revenue
- IONS $705,000,000.00
- BFAM $2,686,013,000.00
- Revenue This Year
- IONS N/A
- BFAM $9.75
- Revenue Next Year
- IONS $10.08
- BFAM $8.01
- P/E Ratio
- IONS N/A
- BFAM $52.85
- Revenue Growth
- IONS N/A
- BFAM 11.07
- 52 Week Low
- IONS $30.23
- BFAM $100.59
- 52 Week High
- IONS $52.34
- BFAM $141.90
- Technical
- Relative Strength Index (RSI)
- IONS 48.36
- BFAM 59.45
- Support Level
- IONS $30.86
- BFAM $115.63
- Resistance Level
- IONS $34.74
- BFAM $130.51
- Average True Range (ATR)
- IONS 1.35
- BFAM 3.11
- MACD
- IONS 0.18
- BFAM 0.55
- Stochastic Oscillator
- IONS 46.34
- BFAM 73.12
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.
About BFAM Bright Horizons Family Solutions Inc.
Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.